RecruitingNot Applicable

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

Germany, United Kingdom200 participantsStarted 2024-01-29

Plain-language summary

The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU) * Signed a valid, IRB/EC/REB-approved informed consent form Exclusion Criteria: * Meets any contraindications per locally applicable Directions for Use (DFU) * Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments

What they're measuring

Change in patient's quality of life (QoL) during the study as compared with baseline

Timeframe: Up to 24-Months

Trial details

NCT IDNCT06553625

SponsorBoston Scientific Corporation

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2035-12

Contact for this trial

Stephanie Delvaux

855-213-9890 BSNClinicalTrials@bsci.com

View on ClinicalTrials.gov More Parkinson Disease trials